Article Sidebar

PDF
Date Published: 13/03/2022
Abstract Views: 455
Views PDF: 259
DOI: https://doi.org/10.51298/vmj.v510i2.1953
Issue
Vol. 510 No. 2 (2022)
Section
Các bài báo
How to Cite
Việt Hoà, T. ., Bùi Quý Quyền, Đào ., & Trung Vinh, H. . (2022). SURVEY ON BONE DENSITIES BY DEXA METHOD IN PATIENTS WITH LUPUS NEPHRITIS. Vietnam Medical Journal, 510(2). https://doi.org/10.51298/vmj.v510i2.1953

SURVEY ON BONE DENSITIES BY DEXA METHOD IN PATIENTS WITH LUPUS NEPHRITIS

Trần Việt Hoà1,, Đào Bùi Quý Quyền2, Hoàng Trung Vinh3
1 Bao Anh Clinic, Trang Bom district, Dong Nai province
2 Cho Ray Hospital
3 Military Hospital 103, Vietnam Military Medical University

Main Article Content

Abstract

Objectives: Investigation of bone density by dual-energy X-ray (DEXA) in patients with systemic lupus erythematosus who have been receiving long-term corticosteroid therapy. Subjects and methods: Cross-sectional study of 83 patients diagnosed with lupus nephritis. All patients were measured bone density to evaluate bone deficiency, osteoporosis by DEXA method. Results: The mean age of patients with lupus nephritis was 28.13 ± 9.21, the rate of male was 13.3%, female accounted for 86.7%. The mean duration of steroid treatment was 39.44 ± 43.74 months. The average value of bone density at the femoral neck is 0.72 ± 0.15 g/cm2; in the pelvis area is 0.82 ± 0.17 g/cm2. The percentage of patients with osteoporosis accounted for 38.55%, osteoporosis accounted for 8.44%. Conclusion: Decreased bone density is a common in patients with lupus nephritis.

Article Details

Keywords

Lupus nephritis, DEXA method, bone density, osteoporosis

References

1. Trịnh Ngọc Duy (2008). Một số đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị bệnh lupus ban đỏ hệ thống tại khoa dị ứng - miễn dịch lâm sàng bệnh viện Bạch Mai năm 2007, Chuyên nghành miễn dịch dị ứng, Đại học Y Hà nội.
2. Vương Tuyết Mai, Đàm Minh Sơn (2013).Tìm hiểu một số đặc điểm lâm sàng và cận lâm sàng của hội chứng thận hư do viêm cầu thận lupus. Tạp chí Y học thực hành;878 (8): 75-78.
3. Ahn SS, Yoo J, Jung SM, et al. (2020). Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrol. 21: 258.
4. Boone JB, Wheless L, Camai A, et al. (2021).Low prevalence of bone mineral density testing in patients with systemic lupuserythematosus and glucocorticoid exposure. Lupus. 30(3): 403–411.
5. Gasparotto M, Gatto M, Binda V, et al. (2020). Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford); 59(Suppl 5): v39–v51.
6. Jung JY, Choi ST, Park SH, et al. (2020).Prevalence of osteoporosis in patients with systemic lupus erythematosus: A multicenter comparative study of the World Health Organization and fracture risk assessment tool criteria. Osteoporos Sarcopenia. 6(4): 173–178.
7. Rekvig OP. (2019). The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be. Front Immunol. 10: 1104.
8. Resende AL, dos Reis LM, Dias CB, et al. (2014).Bone Disease in Newly Diagnosed Lupus Nephritis Patients. PLoS One. 9(9): e106728.